JP2001122795A - Prophylactic and therapeutic agent for infectious disease - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a prophylactic and therapeutic agent for infectious diseases excellent in safety and having excellent effects. SOLUTION: This prophylatic and therapeutic agent for the infectious diseases comprises Echinacea purpurea, Echinacea pallida and Echinacea angustifolia or an extract thereof and a root of Isatis tinctoria L. of the family Cruciferae and a root of Baphicacanthes cusia Bremek. of the family Acanthaceae or an extract thereof as active ingredients.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a prophylactic / therapeutic agent for various infectious diseases, in which echinacea is used in combination with roots.

[0002]

BACKGROUND OF THE INVENTION Infectious diseases caused by viruses and bacteria, such as influenza virus, sometimes become epidemic and cause many deaths. For this reason, there is a demand for the development of a preparation that can be used on a daily basis for the purpose of preventing and treating infectious diseases caused by viruses and bacteria. By the way, in recent years, safety has been strongly demanded for medicines and foods, and for the above-mentioned infectious disease preventive / therapeutic agents, those having a highly safe component as an active ingredient are desired.

Accordingly, an object of the present invention is to provide a prophylactic / therapeutic agent for infectious diseases which is excellent in safety and has excellent effects.

[0004]

Means for Solving the Problems The present inventors have focused on herbal medicines whose safety has been sufficiently proven. Surprisingly, the combination of the indigo root, which is used as a remedy for influenza in China and other countries, and the echinacea, which has been used as an external medicine for burns and insect stings, or as an oral medicine for toothache and headache, Found that both act synergistically, exhibit extremely excellent effects of preventing and treating infectious diseases, and are effective as agents for preventing and treating infectious diseases.

That is, the present invention relates to an echinacea (Echina
cea purpurea, E. pallida and E. angustifolia) or an extract thereof, and an indigo root (Brassicaceae Suzu indigo Isatis tinctor)
ia L. and the fox-finch horse, Ai Baphicacanthes cusia
The present invention provides a prophylactic / therapeutic agent for infectious diseases, which contains Bremek. Root) or an extract thereof as an active ingredient.

[0006]

DETAILED DESCRIPTION OF THE INVENTION Echinacea has been used by indigenous people in North America as a topical medicine for wounds, burns, lymph node swelling, insect stings, toothache, neck pain, headache, gastric spasm, etc. Was. In addition, it is used in China as a remedy for hepatitis, influenza, Japanese encephalitis, mumps, shingles, tonsillitis and the like. Although both were excellent in safety, their preventive and therapeutic effects on infectious diseases were not sufficient. However, it has never been known that the combined use of both of them exhibits extremely excellent preventive and therapeutic effects against infectious diseases such as influenza.

[0007] In the present invention, Echinacea purp (Echinacea purp.)
urea, E. pallida and E. angustifolia) can also be used. In addition, as long as they exhibit the effect of preventing or treating infectious diseases, roots of closely related plants of the indigo plant (Brassicaceae Suzu indigo and the foxtail Sesinaceae Indigo) can also be used.

[0008] Echinacea and lantern roots may use the crude drug as it is or an extract thereof.
Echinacea's crude drug is one or more of roots, leaves, petiole, stem, seed, or whole plant, or dried,
It is cut and crushed. The crude drug of the roots of the lantern is dried or cut and crushed. These may use a commercial item.

[0009] The extract refers to the roots and leaves of echinacea, or the roots of the indigo plant, which are dried or pulverized without drying, and then extracted with a solvent at room temperature or under heating, or a soxhlet extractor or the like. Refers to an extraction solvent solution, a diluting solution or a concentrated solution thereof, or a dried powder thereof obtained by extraction using an extracting device described above.

Solvents used for extraction include water, alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; methyl acetate, ethyl acetate and the like. Esters of
Chain or cyclic ethers such as tetrahydrofuran and diethyl ether; halogenated hydrocarbons such as dichloromethane; hydrocarbons such as n-hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as toluene; Ethers; pyridines and the like, and one or more of these can be used. Of these, water and / or ethanol are preferred.

The extraction is performed, for example, as follows. A solvent is added to echinacea leaves, roots and the like, or roots of indigo plants, or dried, cut, and pulverized materials thereof, preferably at 1 to 120 ° C, particularly preferably 5 to 100 ° C, and preferably 0.1 to 100 ° C. Extraction is carried out for 1 to 30 days, particularly preferably for 1 to 15 days. Next, an extract can be obtained by appropriately filtering and allowing the obtained liquid to stand. Alternatively, the extract may be diluted, concentrated, or lyophilized, and then prepared in a powder or paste form and appropriately formulated. Further, if necessary, purification treatment such as deodorization and decolorization may be performed by a known method.
The extract may be used in this way,
Alternatively, a commercially available product may be used.

The agent for preventing or treating infectious diseases of the present invention can be applied to infectious diseases derived from viruses, bacteria, fungi and the like. Among them, it works more effectively against infectious diseases such as trachea, respiratory tract, digestive tract and urinary tract. In addition, it works particularly effectively against influenza, flu and cold.

The agent for preventing or treating infectious diseases of the present invention can be used as a medicine or food. When used as a medicament, examples of the administration form include oral administration, enteral administration, suppositories, and intravenous administration, and internal administration is preferable. Specific examples include solid preparations such as powders, granules, hard capsules, soft capsules, pills and tablets, and liquid preparations such as syrups, suspensions and emulsions. These orally administered drugs include, in addition to echinacea and roots, excipients such as cellulose and its derivatives, starch and its derivatives, excipients such as natural and synthetic polymers, and stearic acid, which are generally used depending on the form of the orally administered drug. Add lubricants such as higher fatty acids and their salts, natural and synthetic waxes, disintegrants, flavoring agents, binders, oily components, surfactants, alcohols, water, sweeteners, sugars, acidulants, flavors, etc. Can be produced according to a conventional method.

Examples of the food include health foods, functional foods, foods for specified health use, and the like. Specific examples include tablets, granules, powders, powdered drinks, gel or semi-gel foods such as yogurt, drinks such as lactic acid bacteria drinks, and solid foods such as chocolate. Among them, it is particularly preferable to use a powdered beverage. These foods are
In addition to the echinacea and the indigo root, commonly used raw materials are added according to the form of the food, and the food can be produced according to a conventional method.

The total amount of echinacea and roots in the infectious disease prophylactic / therapeutic agent of the present invention is not particularly limited. It is preferably 0.5 to 80% by weight in terms of conversion. In the case of a liquid such as a solution, an emulsion, and a suspension, the content is preferably 0.1 to 20% by weight in terms of undried crude drug. There is no particular limitation on the mixing ratio of Echinacea and lantern, but 0.000
4: 99.9996 to 85:15 is preferred.

The dosage of the prophylactic / therapeutic agent for infectious diseases of the present invention depends on the age, sex and degree of medical condition, but is equivalent to 24 to 2400 m / day for adults per day in terms of virgin crude drug.
g, indigo root is preferably 0.5 to 50 g, echinacea is particularly preferably 50 to 1500 mg, and indigo root is particularly preferably 1.0 to 40 g. It is preferable to administer such an amount in 1 to several times a day, especially 2 to 5 times.

[0017]

EXAMPLES Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.

Example 1 Confirmation of Effect of Infectious Disease Prevention / Treatment Agent of the Present Invention on Influenza Virus Infection of BALB / c Mice Echinacea Extract Powder was manufactured by Nippon Shokubai Pharmaceutical Co., Ltd. “Echinacea Extract Powder” (Root of Echinacea). The mixture was roughly cut, 30% ethanol was added to the crude product 5 times by weight, and the mixture was extracted at room temperature for 2 days. The extract was filtered through a 120-mesh stainless steel wire mesh, and the residue was further 5 times by weight with 30% ethanol. In addition, the mixture was extracted at room temperature for 1 day, filtered in the same manner, then combined, concentrated under reduced pressure (150 mmHg or less) at 60 ° C. or less, and then spray-dried (yield about 12.5
%): 1 g of the echinacea extract corresponds to about 8 g of the undried crude drug. ) (The same applies to the following examples). The indigo root extract powder was produced by the following method. That is, the roots of Suzu indigo were roughly cut, and 10 parts by weight of normal water was added to the roughly cut product, extracted at 100 ° C. for 60 minutes, and the extract was filtered through a 120-mesh stainless steel wire mesh. To the residue was added 10 times by weight of ordinary water, extracted at 100 ° C. for 60 minutes, and filtered in the same manner. Then, the two filtrates were combined and 60
After concentrating under reduced pressure (150 mmHg or less) at a temperature of not more than 0 ° C., it was spray-dried to produce a root extract powder (yield: about 10%).
1 g of the indigo root extract powder corresponds to about 10 g of undried crude drug (the same applies to the following examples).

BALB / c female mice were divided into four groups of three mice per group. The first group was water, the second group was Echinacea extract powder 50 mg / kg body weight per day, and the third group was a blue root extract powder. Was administered orally at a dose of 1 g / kg body weight / day, and the fourth group was orally administered with echinacea extract powder 25 mg / kg body weight / day and lantern root extract powder 0.5 g / kg body weight / day for 7 days. Subsequently, each mouse was anesthetized by injecting amobarbital sodium solution into the peritoneal cavity, and the mouse-infected influenza virus A / PR / 8/34 was injected.
Was infected by instillation through the nostrils. Water and each extract powder were orally administered to each group of mice under the same conditions as above for another 4 days after the infection. On day 5 after the influenza virus infection, the trachea and lungs were excised, and bovine serum albumin (BS
Washing was performed with a phosphate buffer containing A) and an antibiotic to obtain a bronchoalveolar lavage fluid. The wash was then diluted to an appropriate concentration with Eagle's minimal medium containing BSA and antibiotics,
adin-Darby canine liver (MDCK) cells,
The cells were cultured at 37 ° C. for 3 days in the presence of 5% CO ₂ . Then
Viruses infected MDCK cells and cytopathic ones were counted to determine the number of viruses. Table 1 shows the numbers of influenza viruses in the mice of each group and the virus reduction rates of the mice in the second to fourth groups with respect to the mice in the first group.

[0020]

[Table 1]

The virus counts of the mice of the second and third groups were as follows:
Although the virus number was lower than that of the mice in the first group, the reduction rate was lower in all groups. In contrast, the number of viruses in the mice of the fourth group was 1/10 of the number of viruses in the mice of the first group.
It decreased to about 0. From these results, it was confirmed that the combined use of Echinacea and Panglai roots has a high effect of preventing and treating influenza infection.

Example 2 Confirmation of the effect of the preventive / therapeutic agent for infectious diseases of the present invention on a person with poor physical condition due to flu or cold Powdered beverages 1 to 4 were prepared according to a conventional method using the formulations shown in Table 2. Then, these were added and dissolved by adding water so that the total amount was 120 mL, and beverages 1 to 4 were prepared.

[0023]

[Table 2]

16 persons (25-50 years old) who have symptoms of sore throat, runny nose or nasal congestion due to flu or cold
Are divided into 4 groups, each group consisting of 4 people, and the first group has beverage 1 and the second
Group 2 had drink 2, group 3 had drink 3, and group 4 had drink 4 three times a day. Next, the change in physical condition on the next day of drinking was evaluated on a four-point scale: markedly improved, improved, unchanged, and worsened. In addition, the subject was asked to drink without notifying the contents of the beverage. Table 2 shows the results.

In the fourth group, no one improved in physical condition. In addition, the second group and the third group did not always have a sufficient effect of improving the physical condition. On the other hand, in the first group, the effect of improving the physical condition was remarkable. From these results, the effects of the agent for preventing and treating infectious diseases of the present invention on flu and cold were confirmed.

Powdered beverages were prepared according to a conventional method with the composition shown in Table 3. The powdered beverage exhibited an excellent infectious disease prevention / treatment effect.

[0027]

[Table 3]

Tablets having the composition shown in Table 4 were produced according to a conventional method. The tablets exhibited excellent infectious disease prevention / treatment effects.

[0029]

[Table 4]

[0030]

EFFECT OF THE INVENTION The infectious disease preventive / therapeutic agent of the present invention is a combination of echinacea and roots of indigo, which is extremely safe and prevents various infectious diseases, especially influenza, flu, cold and the like. Effective for treatment.

 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Mayumi Nakamoto, Inventor 1075-2 Kita-Namiro, Yuki City, Ibaraki Prefecture Nissui Pharmaceutical Co., Ltd. Pharmaceutical Co., Ltd. (72) Inventor Fumio Ichikawa 1075-2 Kita-Namiro, Yuki City, Ibaraki Prefecture Nissui Pharmaceutical Co., Ltd. F-term (reference) 4C088 AB12 AB15 AC01 BA08 MA07 MA43 ZB33

Claims (3)

[Claims] [Claim 1] Echinacea (Echinacea purpurea, E.pa)
llida and E. angustifolia) or an extract thereof, and an indigo root (the roots of Brassicaceae Suzu indigo (Isatis tinctoria L.) and the fox-flea beetle (Baphicacanthes cusia Bremek.))
Or a prophylactic / therapeutic agent for an infectious disease, comprising an extract thereof and an active ingredient thereof. 2. The preventive / therapeutic agent for an infectious disease according to claim 1, which is taken internally. 3. The prophylactic / therapeutic agent according to claim 2, which is a powdered beverage.